Severe Acute Respiratory-Syndrome Treatment Market Share, Trend Analysis, Key Drivers, Size And Forecast To 2033

"The new report published by The Business Research Company, titled Severe Acute Respiratory-Syndrome Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the severe acute respiratory-syndrome treatment market size has grown rapidly in recent years. It will grow from $2.99 billion in 2023 to $3.45 billion in 2024 at a compound annual growth rate (CAGR) of 15.3%. The severe acute respiratory-syndrome treatment market size is expected to see rapid growth in the next few years. It will grow to $6.12 billion in 2028 at a compound annual growth rate (CAGR) of 15.4%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13027&type=smp

Surging Respiratory Disease Cases Fuel Growth In The Severe Acute Respiratory Syndrome Treatment Market
The growing incidence of respiratory diseases is expected to propel the growth of the severe acute respiratory syndrome treatment market going forward. Respiratory diseases refer to a group of medical conditions that affect the respiratory system responsible for breathing and the exchange of gases between the body and the external environment. Severe acute respiratory syndrome treatment is used in respiratory diseases to alleviate symptoms, prevent respiratory failure, reduce inflammation and maintain oxygen levels. For instance, in June 2023, according to reports shared by the Australian Institute of Health and Welfare, an Australia-based national agency, there was a rise in respiratory disease-related deaths from 43,031 in 2020 to 46,551 in 2021 in Australia. Therefore, the growing incidence of respiratory diseases is driving the growth of the severe acute respiratory syndrome treatment market.

Leading Companies In The Severe Acute Respiratory Syndrome Treatment Market Pioneering Multiplexed Real-Time Pcr Techniques
Major companies operating in the severe acute respiratory syndrome treatment market are developing innovative techniques, such as multiplexed real-time PCR, to sustain their position in the market. Multiplexed real-time PCR is a molecular biology technology that permits the amplification and detection of numerous DNA or RNA targets in a single procedure. For instance, in July 2022, TransGen Biotech Co. Ltd., a Beijing-based researcher and manufacturer of molecular and cellular biology products, launched the Trans-SARS-CoV-2, Influenza A and B and Respiratory Syncytial Virus Assay. This innovative assay is a multiplexed real-time PCR (polymerase chain reaction) assay that can be used to detect and differentiate between severe acute respiratory syndrome COVID-19 2 (SARS CoV 2), Influenza A, Influenza B and respiratory syncytial virus (RSV) in a single specimen. Additionally, it is a valuable tool for diagnosing and treating SARS, influenza and RSV, which can help guide treatment and prevent the spread of these diseases.

The severe acute respiratory-syndrome treatment market covered in this report is segmented -

1) By Drug Class: Antibiotics; Antiviral; Corticosteroids; Monoclonal Antibodies; Other Drug Classes
2) By Route Of Administration: Oral; Intravenous
3) By Indication: Severe Acute Respiratory Syndrome COVID-19 (SARS-CoV); Severe Acute Respiratory Syndrome COVID-19 2 (SARS‑CoV‑2)
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13027&type=discount

Major players in the severe acute respiratory-syndrome treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck And Co Inc., Novartis AG, Bristol Myers Squib company, GlaxoSmithKline PLC, AstraZeneca PLC, Sanofi SA, Eli Lilly And Company, Gilead Sciences Inc., Amgen Inc., Johnson And Johnson Private Limited, Moderna Inc., Regeneron Pharmaceuticals Inc., Hetero labs Ltd., Alexion Pharmaceuticals Inc., Cadila healthcare Ltd., Genentech Inc., Cipla Ltd., Biogen Inc., Vir Biotechnology Inc., Swedish Orphan Biovitrum AB, Dynavax Technologies Corporation, ViiV Healthcare Limited, Panacea Biotec Limited, CureVac N.V., CN Bio Innovations Ltd., Inovio Pharmaceuticals Inc., Chimerix Inc.

Contents of the report:
1. Executive Summary
2. Severe Acute Respiratory-Syndrome Treatment Market Report Structure
3. Severe Acute Respiratory-Syndrome Treatment Market Trends And Strategies
4. Severe Acute Respiratory-Syndrome Treatment Market - Macro Economic Scenario
5. Severe Acute Respiratory-Syndrome Treatment Market Size And Growth
…..
27. Severe Acute Respiratory-Syndrome Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/severe-acute-respiratory-syndrome-treatment-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.